Recombinant rhesus IGFBP2 (XP_001087071.1) (Met1-Gln324) was expressed, fused with a polyhistidine tag at the C-terminus.
Predicted N Terminal:
Lyophilized from sterile PBS, pH 7.4, 5%~8% trehalose and mannitol.
Measured by its ability to inhibit the biological activity of IGFI or IGFII on MCF7 human breast adenocarcinoma cells. The ED50 for this effect is typically 0.02-0.1 μg/mL in the presence of 14 ng/mL human IGFII.
The recombinant rhesus IGFBP2 comprises 300 amino acids and has a calculated molecular mass of 32.8 KDa.
< 1.0 EU per μg of the protein as determined by the LAL method.
>67 % as determined by SDS-PAGE.
Samples are stable for up to twelve months from date of receipt at -70ºC.
Store it under sterile conditions at -20ºC~-70ºC. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
It is recommended that sterile water be added to the vial to prepare a stock solution of 0.25 ug/ul. Centrifuge the vial at 4ºC before opening to recover the entire contents.